Original FTC V. Actavis Case Ends With AbbVie AndroGel Deal
AbbVie Inc. has agreed not to enter settlements that illegally delay the entry of certain generic drugs, allowing it to avoid a related trial over its testosterone treatment AndroGel slated to...To view the full article, register now.
Already a subscriber? Click here to view full article